Amundi Has $2.62 Million Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Amundi increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 42.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,871 shares of the medical device company's stock after acquiring an additional 20,970 shares during the period. Amundi owned about 0.11% of Tandem Diabetes Care worth $2,619,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Brooklyn Investment Group bought a new position in shares of Tandem Diabetes Care in the third quarter valued at about $28,000. Assetmark Inc. bought a new position in Tandem Diabetes Care in the 3rd quarter worth approximately $29,000. Jones Financial Companies Lllp lifted its holdings in Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after buying an additional 748 shares in the last quarter. McIlrath & Eck LLC bought a new position in Tandem Diabetes Care in the 3rd quarter valued at $52,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after buying an additional 1,101 shares during the period.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.20% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities analysts have recently issued reports on TNDM shares. Robert W. Baird cut their price target on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a research note on Thursday, February 27th. Morgan Stanley cut shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Canaccord Genuity Group restated a "buy" rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Finally, The Goldman Sachs Group cut their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $45.38.

Tandem Diabetes Care Stock Up 0.2 %

Shares of NASDAQ:TNDM traded up $0.04 during midday trading on Thursday, hitting $20.66. The stock had a trading volume of 721,445 shares, compared to its average volume of 1,473,616. The company has a market cap of $1.37 billion, a P/E ratio of -10.70 and a beta of 1.45. The business's 50-day simple moving average is $30.35 and its 200-day simple moving average is $34.11. Tandem Diabetes Care, Inc. has a 12 month low of $17.64 and a 12 month high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.